for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Quest Diagnostics Inc

DGX

Latest Trade

145.71USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

113.36

 - 

160.56

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
145.71
Open
--
Volume
--
3M AVG Volume
26.11
Today's High
--
Today's Low
--
52 Week High
160.56
52 Week Low
113.36
Shares Out (MIL)
130.64
Market Cap (MIL)
17,559.82
Forward P/E
12.06
Dividend (Yield %)
1.73

Next Event

Q3 2021 Quest Diagnostics Inc Earnings Release

Latest Developments

More

Quest Diagnostics Says A Unit Of Co Experienced A Data Security Incident

Quest Diagnostics Updates Outlook For Full Year 2021

Quest Diagnostics Acquires Boca Raton-Based Nationwide Laboratory Services

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Quest Diagnostics Inc

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates under two segments: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services develops and delivers diagnostic testing information and services, providing insights that enables a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers, and accountable care organizations (ACOs). Its Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers, and its healthcare information technology businesses, which offers solutions for healthcare providers. The Company's services are provided under the Quest Diagnostics brand, and other brands, such as AmeriPath, Dermpath Diagnostics, ExamOne, Quanum. It also helps in delivering diagnostic insights for COVID-19 and a range of other medical conditions for communities in South Florida.

Industry

Healthcare Facilities

Contact Info

500 Plaza Dr

SECAUCUS, NJ

07094-3619

United States

+1.973.5202700

https://www.questdiagnostics.com/

Executive Leadership

Stephen H. Rusckowski

Chairman of the Board, President, Chief Executive Officer

Mark J. Guinan

Chief Financial Officer, Executive Vice President

James E. Davis

Executive Vice President, General Diagnostics

Michael E. Prevoznik

Senior Vice President, General Counsel

Catherine T. Doherty

Senior Vice President, Group Executive - Clinical Franchise Solutions and Marketing

Key Stats

2.11 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

7.5K

2019

7.7K

2020

9.4K

2021(E)

10.0K
EPS (USD)

2018

6.310

2019

6.560

2020

11.180

2021(E)

11.919
Price To Earnings (TTM)
8.57
Price To Sales (TTM)
1.59
Price To Book (MRQ)
2.97
Price To Cash Flow (TTM)
6.64
Total Debt To Equity (MRQ)
67.98
LT Debt To Equity (MRQ)
67.94
Return on Investment (TTM)
20.31
Return on Equity (TTM)
17.45

Latest News

Latest News

UPDATE 1-Quest Diagnostics raises 2021 profit outlook on uptick in COVID-19 testing

U.S. laboratory Quest Diagnostics Inc raised its full-year profit outlook on Thursday, saying it expects an uptick in COVID-19 testing demand due to the surge in infections from the Delta variant of the coronavirus.

Quest Diagnostics raises 2021 profit outlook on uptick in COVID-19 testing

Quest Diagnostics Inc raised its full-year profit outlook on Thursday, saying it expects an uptick in COVID-19 testing demand due to the surge in infections from the Delta variant of the coronavirus.

Quest Diagnostics sees uptick in COVID-19 testing as Delta variant spreads

U.S. laboratory Quest Diagnostics Inc said on Thursday demand for COVID-19 testing had increased since the end of June as the more infectious Delta variant spreads across the country.

BRIEF-Quest Diagnostics Exec Says Rise in COVID-19 Testing To Some Extent Due To Delta Variant: Conf Call

* QUEST DIAGNOSTICS EXECUTIVE SAYS IN RECENT WEEKS, HAVE SEEN COVID-19 PCR TESTING VOLUMES STABILIZE AND INCREASE MODESTLY: CONF CALL

Abbott beats profit estimates as medical device sales rebound

Abbott Laboratories beat quarterly profit estimates on Thursday, driven by a rebound in its non-COVID-19 testing business and sales of its medical devices as vaccinations encouraged Americans to resume non-urgent procedures.

Quest Diagnostics quarterly profit rises more than three-fold

Major U.S. laboratory Quest Diagnostics Inc posted a 241% rise in second-quarter profit on Thursday, as vaccine rollouts and a drop in COVID-19 cases spurred a recovery in its core non-coronavirus testing businesses.

Quest sees waning demand for COVID-19 tests, rebound in core U.S. business as pandemic subsides

Quest Diagnostics Inc on Thursday reported a first-quarter profit that exceeded Wall Street expectations as a recovery in its non-COVID-19 businesses offset a slowdown in coronavirus testing.

Abbott sales miss signals slowing COVID-19 tests demand as vaccinations take off

Abbott Laboratories fell short of first-quarter revenue estimates on Tuesday due to easing demand for some of its COVID-19 tests, stoking fears of slowing growth for the business as vaccinations gain steam across the globe.

Abbott's results a litmus test for COVID-19 testing demand

Investors will be squarely focused on Abbott Laboratories results on Tuesday to assess the impact of swift vaccination rollout on demand for the company's COVID-19 tests.

Testing lab says ex-Amazon worker can't sue over failed drug test

Quest Diagnostics has urged a federal judge to dismiss a former Amazon employee's claims that the lab-testing company violated Pennsylvania law by reporting his positive test for marijuana without telling Amazon he was using it for medical reasons.

Quest beats profit estimates on demand for COVID-19 tests as cases surged

Medical device maker Quest Diagnostics Inc's quarterly profit beat estimates on Thursday, boosted by robust demand for its COVID-19 testing services as coronavirus infections surged in the United States.

Quest Diagnostics quarterly profit more than doubles on robust COVID-19 test demand

Quest Diagnostics Inc on Thursday posted a near 129% rise in quarterly profit on robust demand for the clinical lab operator's COVID-19 testing services.

BRIEF-U.S. FDA Says Authorizes First Covid-19, Flu Combination Test For Use With Home-Collected Samples

* U.S. FDA SAYS AUTHORIZES FIRST COVID-19 AND FLU COMBINATION TEST FOR USE WITH HOME-COLLECTED SAMPLES

Quest Diagnostics reports rise in turnaround time on COVID-19 testing demand surge

Quest Diagnostics Inc <DGX.N> said on Tuesday the nationwide surge in coronavirus cases has led to a slight increase in turnaround time for its COVID-19 testing.

Quest raises profit forecast as COVID-19 tests demand to jump

Quest Diagnostics Inc raised its full-year earnings expectations on Thursday after a strong quarterly beat and forecast robust demand for COVID-19 tests during the fall season and into 2021.

Quest Diagnostics third-quarter profit more than doubles

Quest Diagnostics Inc reported a 164% rise in third-quarter profit on Thursday, as demand for tests offered by the clinical lab operator recovered on easing of COVID-19 related restrictions.

FACTBOX-Drugmakers rush to develop COVID-19 treatments

Drugmakers around the world are rushing to develop treatments for COVID-19, the respiratory disease caused by the novel coronavirus that has killed hundreds of thousands. Several companies are developing antibody treatments, similar to Regeneron Pharmaceutical Inc's treatment...

Walmart to test drone delivery of COVID-19 test kits

Walmart Inc said on Tuesday it would run a pilot project to deliver self-collection test kits for coronavirus through automated drones at customers' doorsteps.

Breakingviews - Corona Capital: Testing, Flights, Football

Corona Capital is a column updated throughout the day by Breakingviews columnists around the world with short, sharp pandemic-related insights.

Quest Diagnostics raises 2020 profit, revenue forecast

Quest Diagnostics <DGX.N> on Thursday raised its full-year revenue and profit forecast, benefiting from growing demand for its non-COVID-19 testing services.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up